Alkem Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 20-Feb-2026.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Midcap 150 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Labs' board, at its 13 Feb 2026 meeting, approved consolidated Q3FY26 revenue of Rs. 3,737 crore (up ~11% YoY from Rs. 3,374 crore) and 9MFY26 revenue of Rs. 11,109 crore (up ~13% YoY). Consolidated net profit for Q3 rose to Rs. 653 crore from Rs. 641 crore YoY, while 9M profit grew to Rs. 2,100 crore from Rs. 1,893 crore. The board declared an interim dividend of Rs. 43 per share (2,150% on face value of Rs. 2), with 20 Feb 2026 as record date and payment from 6 Mar 2026. Results include an exceptional charge of Rs. 52.8 crore related to new Labour Codes, partly offset by a Rs. 14.3 crore gain from the earlier sale of the Indore manufacturing facility. The generic business was transferred to subsidiary Alkem Wellness Ltd effective 1 Oct 2025 and is shown as discontinued operations.
Shareholders holding shares as of 20 Feb 2026 will receive the Rs. 43 interim dividend, a meaningful payout that signals continued cash generation despite one-time Labour Code costs. Steady revenue and profit growth suggest business momentum is intact, which is supportive for the stock near-term, though dividend yield level cannot be verified from the filing alone.